# ScoreItem: Hepatite C - Anti-HCV

**ID:** `019bf31d-2ef0-76ad-8f5b-7d67b26ef877`
**FullName:** Hepatite C - Anti-HCV (Exames - Laboratoriais)
**Unit:** Qualitativo

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 17 artigos
- Avg Similarity: 0.523

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-76ad-8f5b-7d67b26ef877`.**

```json
{
  "score_item_id": "019bf31d-2ef0-76ad-8f5b-7d67b26ef877",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Hepatite C - Anti-HCV (Exames - Laboratoriais)
**Unidade:** Qualitativo

**30 chunks de 17 artigos (avg similarity: 0.523)**

### Chunk 1/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.652

of the degree of liver fibrosis 
in chronic HCV patients on long-term haemodialysis. 
Nephrol Dial Transplant 2000;15:1716-7.69. Mardini H, Record C. Detection assessment and 
monitoring of hepatic fibrosis: biochemistry or biopsy? 
Ann Clin Biochem 2005;42:441-7.70. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani 
ES, Asselah T, et al; ANRS HCEP 23 Fibrostar 
Group. Comparison of nine blood tests and transient 
elastography for liver fibrosis in chronic hepatitis C: the 
ANRS HCEP-23 study. J Hepatol 2012;56:55-62.71. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu 
MD, Grigorescu M. Two or more synchronous 
combination of noninvasive tests to increase accuracy of 
liver fibrosis assessement in chronic hepatitis C; results 
from a cohort of 446 patients. Hepat Mon 2012;12:177-
84.72. Stevenson M, Lloyd-Jones M, Morgan MY, Wong 
R.

---

### Chunk 2/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** discussion | **Similarity:** 0.594

h 
JD, Marrero JA, Conjeevaram HS, et al. A simple 
noninvasive index can predict both significant fibrosis 
and cirrhosis in patients with chronic hepatitis C. 
Hepatology 2003;38:518-26.79. Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of 
simple biomarkers in predicting fibrosis progression in 
HCV infection. World J Gastroenterol 2010;16:5710-5.80. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray 
P, Moussalli J, et al. Prognostic value of liver fibrosis 
biomarkers: a meta-analysis. Gastroenterol Hepatol (N 
Y) 2011;7:445-54.81. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, 
Lemon SM, et al. Mitochondrial injury, oxidative stress, 
and antioxidant gene expression are induced by hepatitis 
C virus core protein. Gastroenterology 2002;122:366-
75.82. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, 
Ferry N, Lacour B, et al. Serum activity of mitochondrial 
aspartate aminotransferase: a sensitive marker of 
alcoholism with or without alcoholic hepatitis.

---

### Chunk 3/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.588

Stevenson M, Lloyd-Jones M, Morgan MY, Wong 
R. Non-invasive diagnostic assessment tools for the 
detection of liver fibrosis in patients with suspected 
alcohol-related liver disease: a systematic review and 
economic evaluation. Health Technol Assess 2012;16:1-
174.73. Chou R, Wasson N. Blood tests to diagnose fibrosis 
or cirrhosis in patients with chronic hepatitis C virus 
infection: a systematic review. Ann Intern Med 
2013;158:807-20.74. Str√°nsk√Ω J, Ryzlov√° M, Stritesk√Ω J, Hor√°k J. 
[Aspartate aminotransferase (AST) more than alanine 
aminotransferase (ALT) levels predict the progression 
of liver fibrosis in chronic HCV infection]. Vnitr Lek 
2002;48:924-8.75. Giannini E, Botta F, Testa E, Romagnoli P, Polegato 
S, Malfatti F, et al. The 1-year and 3-month prognostic 
utility of the AST/ALT ratio and model for end-stage 
liver disease score in patients with viral liver cirrhosis. 

Clin Biochem Rev Vol 34 November 2013   127
Am J Gastroenterol 2002;97:2855-60.76.

---

### Chunk 4/30
**Article:** Hepatitis C Virus: Epidemiological Challenges and Global Strategies (2025)
**Journal:** Viruses
**Section:** abstract | **Similarity:** 0.577

Review of global HCV epidemiology: 1M annual infections, 242K deaths, prison prevalence 17.7%, and elimination strategies.

---

### Chunk 5/30
**Article:** Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen (2024)
**Journal:** Diagnostics (Basel)
**Section:** abstract | **Similarity:** 0.572

Anti-HBc appears early in HBV infection and persists lifelong, crucial for blood safety screening and identifying past exposure. Major challenges: lack of standardization across assay systems (ELISA, CMIA, CLIA, CLEIA) producing results in different units (IU/mL, INH%, S/O), complicating interpretation. Difficulty distinguishing low-titer true positives from false positives with highly sensitive assays. Quantitative anti-HBc predicts treatment response, carcinogenesis risk, reactivation, and HBsAg clearance during therapy.

---

### Chunk 6/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.570

of the AST/ALT ratio and model for end-stage 
liver disease score in patients with viral liver cirrhosis. 

Clin Biochem Rev Vol 34 November 2013   127
Am J Gastroenterol 2002;97:2855-60.76. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the 
aspartate aminotransferase-alanine aminotransferase 
ratio in assessing disease severity and prognosis in 
patients with hepatitis C virus-related chronic liver 
disease. Arch Intern Med 2003;163:218-24.77. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri 
M, Molinaro E, et al. Multivariate discriminant function 
based on six biochemical markers in blood can predict 
the cirrhotic evolution of chronic hepatitis. Clin Chem 
2001;47:1696-700.78. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch 
JD, Marrero JA, Conjeevaram HS, et al. A simple 
noninvasive index can predict both significant fibrosis 
and cirrhosis in patients with chronic hepatitis C. 
Hepatology 2003;38:518-26.79.

---

### Chunk 7/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** discussion | **Similarity:** 0.564

ase (MELD) 
scores.75,76 A raised AST/ALT ratio of only slightly above 1 (1.09) is predictive of the progression of chronic viral hepatitis 
C to cirrhosis.77It is therefore the elevation of AST, rather than ALT, which 
is predictive of fibrosis and other ratios involving AST, such 
as the AST to Platelet Ratio Index (APRI)78 and FIB4 index (which involves the four parameters: AST, ALT, platelets and 
age) are also more predictive.79,80 The reason why the AST is more elevated than ALT with progression of fibrosis is 
uncertain but may be either because of increased production, 
such as mitochondrial release,81,82 or a relatively reduced clearance.83Chronic viral hepatitis may also progress to hepatocellular 
carcinoma, however GGT is the best predictor of this 
complication, while AST is not predictive in multivariate 
analysis and ALT is not predictive at all.84 Alcoholic Hepatitis
The predominance of AST over ALT in alcohol-related liver 
disease was first reported by Harinasuta et a

---

### Chunk 8/30
**Article:** Chronic hepatitis B in 2025: diagnosis, treatment and future directions (2025)
**Journal:** Clinical Medicine (London)
**Section:** abstract | **Similarity:** 0.563

Comprehensive 2025 review on hepatitis B diagnosis emphasizing anti-HBc role in serological pattern interpretation. Highlights common diagnostic pitfall of isolated anti-HBc positivity (typically reflects past exposure, requires management only if immunosuppression planned). Distinguishes anti-HBc IgM (acute infection) from IgG (chronic/resolved). Emphasizes reactivation risk in immunosuppressed anti-HBc-positive patients, particularly with B-cell depleting agents, warranting prophylactic therapy.

---

### Chunk 9/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.559

with chronic 
hepatitis C. Dig Dis Sci 1998;43:2156-9.61. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT 
ratio predicts cirrhosis in patients with chronic hepatitis 
C virus infection. Am J Gastroenterol 1998;93:44-8.62. Anderson FH, Zeng L, Rock NR, Yoshida EM. An 
assessment of the clinical utility of serum ALT and AST 
in chronic hepatitis C. Hepatol Res 2000;18:63-71.63. Assy N, Minuk GY. Serum aspartate but not alanine 
aminotransferase levels help to predict the histological 
features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000;95:1545-50.64. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. 
Aspartate aminotransferase: alanine aminotransferase 
ratio in chronic hepatitis C infection: is it a useful 
predictor of cirrhosis? J Gastroenterol Hepatol 
2000;15:386-90.65. Giannini E, Risso D, Testa R. Transportability and 
reproducibility of the AST/ALT ratio in chronic 
hepatitis C patients. Am J Gastroenterol 2001;96:918-9.66.

---

### Chunk 10/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.544

000;15:386-90.65. Giannini E, Risso D, Testa R. Transportability and 
reproducibility of the AST/ALT ratio in chronic 
hepatitis C patients. Am J Gastroenterol 2001;96:918-9.66. Pohl A, Behling C, Oliver D, Kilani M, Monson P, 
Hassanein T. Serum aminotransferase levels and 
platelet counts as predictors of degree of fibrosis in 
chronic hepatitis C virus infection. Am J Gastroenterol 
2001;96:3142-6.67. Park SY, Kang KH, Park JH, Lee JH, Cho CM, Tak 
WY, et al. [Clinical efficacy of AST/ALT ratio and 
platelet counts as predictors of degree of fibrosis in 
HBV infected patients without clinically evident liver 
cirrhosis]. Korean J Gastroenterol 2004;43:246-51.68. Ust√ºndag Y, Bilezik√ßi B, Boyacioƒülu S, Kayata≈ü M, 
Odemir N. The utility of AST/ALT ratio as a non-
invasive demonstration of the degree of liver fibrosis 
in chronic HCV patients on long-term haemodialysis. 
Nephrol Dial Transplant 2000;15:1716-7.69. Mardini H, Record C.

---

### Chunk 11/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** discussion | **Similarity:** 0.526

u A, Lesgourgues B, 
Ferry N, Lacour B, et al. Serum activity of mitochondrial 
aspartate aminotransferase: a sensitive marker of 
alcoholism with or without alcoholic hepatitis. 
Hepatology 1984;4:893-6.83. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. 
Plasma clearance of intravenously injected aspartate 
aminotransferase isozymes: evidence for preferential 
uptake by sinusoidal liver cells. Hepatology 1985;5:367-
75.84. Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen 
B, et al. Comprehensive analysis of common serum liver 
enzymes as prospective predictors of hepatocellular 
carcinoma in HBV patients. PLoS One 2012;7:e47687.85. Harinasuta U, Chomet B, Ishak K, Zimmerman 
HJ. Steatonecrosis‚ÄîMallory body type. Medicine 
(Baltimore) 1967;46:141-62.86. Cohen JA, Kaplan MM. The SGOT/SGPT ratio‚Äî
an indicator of alcoholic liver disease. Dig Dis Sci 
1979;24:835-8.87. Correia JP, Alves PS, Camilo EA. SGOT-SGPT ratios. 
Dig Dis Sci 1981;26:284.88. Alves PS, Camilo EA, Correia JP.

---

### Chunk 12/30
**Article:** Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections (2023)
**Journal:** Viruses
**Section:** abstract | **Similarity:** 0.521

Demonstrates quantitative anti-HBc (qAnti-HBc) as universal anti-HBV immune surrogate reflecting host immune response. Patients in immune-active phases show ~10-fold higher qAnti-HBc versus immune-tolerant phases. Correlates positively with ALT activity and histological inflammation severity. Cut-off ~4.5 log10 IU/mL diagnoses moderate-to-severe inflammation in normal-ALT patients. Baseline qAnti-HBc >4.0-4.5 log10 IU/mL independently predicts HBeAg seroconversion with antivirals.

---

### Chunk 13/30
**Article:** EASL Clinical Practice Guidelines on the management of hepatitis B virus infection (2025)
**Journal:** Journal of Hepatology
**Section:** abstract | **Similarity:** 0.519

EASL 2025 guidelines on biomarker-led personalized HBV therapy targeting functional cure through sustained HBsAg loss.

---

### Chunk 14/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.516

.56. Gitlin N. The serum glutamic oxaloacetic transaminase/
serum glutamic pyruvic transaminase ratio as a 
prognostic index in severe acute viral hepatitis. Am J 
Gastroenterol 1982;77:2-4.57. Sunheimer R, Capaldo G, Kashanian F, Finck C, Woo 
J, Korins M, et al. Serum analyte pattern characteristic 
of fulminant hepatic failure. Ann Clin Lab Sci 
1994;24:101-9.58. Williams AL, Hoofnagle JH. Ratio of serum aspartate 
to alanine aminotransferase in chronic hepatitis; 
relationship to cirrhosis. Gastroenterology 1988;95:734-
9.59. Cadiot G, Ink O, Boutron A, Hanny P, Laurent-Puig P, 
Buffet C. Mitochondrial aspartate aminotransferase in 
nonalcoholic cirrhosis. Gastroenterology 1989;97:240-
1.60. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 
1 is not diagnostic of cirrhosis in patients with chronic 
hepatitis C. Dig Dis Sci 1998;43:2156-9.61. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT 
ratio predicts cirrhosis in patients with chronic hepatitis 
C virus infection.

---

### Chunk 15/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.507

ALT ratio in acute viral hepatitis survivors 
was 0.3-0.6, while in non survivors the AST/ALT ratio was 
1.2-2.356. The De Ritis ratio therefore reflects the time course of acute viral hepatitis and is generally a vital clue to the 
patient‚Äôs prognosis.57Chronic Viral Hepatitis
AST/ALT ratios below 1.0 are also typical of chronic viral 
hepatitis (e.g. hepatitis B and C), however ratios slightly 
above 1.0 may be found in chronic viral hepatitis but this 
is particularly when progression to fibrosis and cirrhosis is 

Clin Biochem Rev Vol 34 November 2013   121
present.58-66 In chronic hepatitis B patients without clinical evidence of cirrhosis, the presence of progressive fibrosis might be predicted using an AST/ALT ratio over 1.0 however 
the ratio does not go above 2.0 in any patient.67 In chronic hepatitis C the raised AST/ALT ratio similarly correlates 
with fibrosis rather than necroinflammatory activity (e.g.

---

### Chunk 16/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.506

c Univ 
Palacky Olomouc Czech Repub 2005;149:409-11.159. Rosenthal P, Haight M. Aminotransferase as a 
prognostic index in infants with liver disease. Clin 
Chem 1990;36:346-8.160. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, 
Del Vecchio E, et al. Updated definitions of healthy 
ranges for serum alanine aminotransferase levels. Ann 
Intern Med 2002;137:1-10.161. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni 
V, Martins J, Nader H, et al. Noninvasive serum markers 
in the diagnosis of structural liver damage in chronic 

130   Clin Biochem Rev Vol 34 November 2013
hepatitis C virus infection. Liver Int 2006;26:1095-9.162. Mera JR, Dickson B, Feldman M. Influence of gender on the ratio of serum aspartate aminotransferase (AST) 
to alanine aminotransferase (ALT) in patients with and 
without hyperbilirubinemia. Dig Dis Sci 2008;53:799-
802.163. Lazo M, Selvin E, Clark JM.

---

### Chunk 17/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** results | **Similarity:** 0.504

2023,12,310
5of12
3.Results3.1.PatientCharacteristicsThebaselinecharacteristicsof430subjectsareprovidedinTable1,amongwhom86werenon-survivorsand344weresurvivorsatday30.Themedianageofthepatientswas60.5yearsand309patientsweremale(71.9%).Atenrollment,21(4.9%)patientshadlivercirrhosis,58(13.5%)haddiabetes,21(4.9%)hadcongestiveheartfailure,and5(1.2%)hadend-stagerenaldisease.ThemedianinitialASTandALTlevelswere657.0U/Land207.5U/L,respectively.ThemedianpeakASTlevelwas782.0U/L.Table1.Clinicalandlaboratorycharacteristicsofpatients(n=430).

---

### Chunk 18/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.500

Lp(a), APO-B/APO-A, NO) para preven√ß√£o e tratamento da DCV.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Solicitar avalia√ß√£o do √≠ndice de √¥mega 3 e da raz√£o √¥mega 3:√¥mega 6; ajustar suplementa√ß√£o de √¥mega 3 conforme resultados.
- [ ] 2. Dosar vitamina D (25(OH)D) e PTH; estabelecer metas de 80 ng/mL para cardiopatas/hipertensos e considerar >100 ng/mL para autoimunes, com monitoriza√ß√£o de seguran√ßa.
- [ ] 3. Aplicar protocolo de curva de glicose e insulina (jejum, 30, 60, 90, 120 min) para detectar hiperinsulinemia oculta e resist√™ncia √† insulina.
- [ ] 4. Introduzir metformina em casos de resist√™ncia √† insulina, juntamente com plano nutricional coordenado com nutricionista.
- [ ] 5. Avaliar homociste√≠na e intervir com vitaminas B9, B12 e B6 em casos de eleva√ß√£o, considerando polimorfismos de metila√ß√£o.
- [ ] 6.

---

### Chunk 19/30
**Article:** Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline (2026)
**Journal:** CA: A Cancer Journal for Clinicians
**Section:** abstract | **Similarity:** 0.499

Atualiza√ß√£o da diretriz de rastreamento de c√¢ncer cervical da American Cancer Society para incluir autocoleta de esp√©cimes vaginais para teste de HPV. Para mulheres de risco m√©dio, recomenda-se iniciar rastreamento aos 25 anos com teste prim√°rio de HPV a cada 5 anos at√© 65 anos. Para teste prim√°rio de HPV, esp√©cimes cervicais coletados por cl√≠nico s√£o preferidos, mas esp√©cimes vaginais autocoletados s√£o aceit√°veis. Quando esp√©cimes vaginais autocoletados s√£o HPV negativos no rastreamento, recomenda-se repetir teste em 3 anos. Para descontinuar rastreamento, recomenda-se que mulheres de risco m√©dio tenham testes prim√°rios de HPV negativos ou coteste negativo aos 60 e 65 anos. Esta mudan√ßa representa avan√ßo significativo ao aumentar acesso ao rastreamento, particularmente para popula√ß√µes com barreiras ao cuidado tradicional.

---

### Chunk 20/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.498

d 20-year risk of metabolic syndrome, diabetes, 
and cardiovascular disease. Gastroenterology 
2008;135:1935-44.152. Uslusoy HS, Nak SG, G√ºlten M, Bƒ±yƒ±klƒ± Z. Non-
alcoholic steatohepatitis with normal aminotransferase 
values. World J Gastroenterol 2009;15:1863-8.153. Mardini H, Record C. Detection assessment and 
monitoring of hepatic fibrosis: biochemistry or biopsy? 
Ann Clin Biochem 2005;42:441-7.154. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, 
Seeff LB. Diagnosis and monitoring of hepatic injury. 
II. Recommendations for use of laboratory tests in 
screening, diagnosis, and monitoring. Clin Chem 
2000;46:2050-68.155. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. 
Retrospective evaluation of serum markers APRI and 
AST/ALT for assessing liver fibrosis and cirrhosis in 
chronic hepatitis B and C patients with hepatocellular 
carcinoma. Intern Med 2008;47:569-75.156. Sorbi D, Boynton J, Lindor KD.

---

### Chunk 21/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.491

, apoiando a personaliza√ß√£o baseada em perfis de risco cumulativos, n√£o em um √∫nico marcador.
**Achados Adicionais**
- O cardi√¥metro de mortalidade cardiovascular iniciou monitoramento em 11/6/2024, contextualizando a urg√™ncia de interven√ß√µes cont√≠nuas.
- Diretrizes de tratamento costumam usar um limiar de 7,5% de risco para estatinas, mas exemplos pr√°ticos ilustram faixas de 2‚Äì4% em que a decis√£o deve considerar CAC e ApoB.
- Quase 40% dos indiv√≠duos com LDL muito elevado podem n√£o apresentar aterosclerose, refor√ßando heterogeneidade do risco.
- Colesterol total de 300 frequentemente acompanha LDL >190, mas a decis√£o terap√™utica deve ser guiada por risco global.
- Revis√µes de 2019 na Annals of Internal Medicine sobre carne vermelha/processada fornecem contexto adicional para dietas cardiometab√≥licas.
- Editorial de 2020 sobre hipercolesterolemia familiar difundiu o conceito ‚ÄúPower of Zero‚Äù, ampliando o uso do CAC na estratifica√ß√£o.

---

### Chunk 22/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.488

review. 
Acta Derm Venereol
. 
(1997) 77:299¬ñ304. doi: 
10.2340/0001555577299304
 83. Ena, P, Lorrai, P, Pintus, A, Marras, V, and Dessy, LA. Development of multifocal 
squamous cell carcinoma in lichen sclerosus et atrophicus of the penis associated to HCV 
hepatitis. 
Andrologia
. (2004) 36:38¬ñ40. doi: 
10.1046/j.1439-0272.2003.00600.x
 84. Boulinguez, S, Bernard, P, Lacour, JP, Nicot, T, Bedane, C, Ortonne, JP, et al. Bullous 
lichen sclerosus with chronic hepatitis C virus infection. 
Br J Dermatol
. (1997) 137:474¬ñ6. 
doi: 
10.1111/j.1365-2133.1997.tb03767.x
 85. Cong, Q, Guo, X, Zhang, S, Wang, J, Zhu, Y, Wang, L, et al. HCV poly U/UC 
sequence-induced inammation leads to metabolic disorders in vulvar lichen sclerosis. 
Life 
Sci Alliance
. (2021) 4:e202000906. doi: 
10.26508/lsa.202000906
 86. Shim, TN, and Bunker, CB. Male genital lichen sclerosus and hepatitis C. 
Br J 
Dermatol
. (2012) 167:1398¬ñ9. doi: 
10.1111/j.1365-2133.2012.11065.x
 87.

---

### Chunk 23/30
**Article:** Occult Hepatitis B Virus Infection: An Update (2022)
**Journal:** Viruses
**Section:** abstract | **Similarity:** 0.487

Occult HBV infection (OBI): HBsAg-negative with replication-competent HBV DNA in liver. Seropositive OBI (~80%): anti-HBc/anti-HBs detectable; seronegative OBI (~20%): all markers absent. Anti-HBc serves as surrogate marker for OBI screening in blood donors, organ recipients, immunosuppressed patients. Reactivation occurs in up to 40% with immunosuppression (highest risk: anti-CD20 therapies >10%; moderate: chemotherapy/TNFŒ± inhibitors 1-10%). OBI accelerates cirrhosis in concurrent liver disease, maintains oncogenic potential (HBV integration in 75% OBI-HCC). Prophylactic antivirals recommended for high-risk immunosuppression in anti-HBc-positive patients.

---

### Chunk 24/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.484

hepatitis B and C patients with hepatocellular 
carcinoma. Intern Med 2008;47:569-75.156. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate 
aminotransferase to alanine aminotransferase: potential 
value in differentiating nonalcoholic steatohepatitis 
from alcoholic liver disease. Am J Gastroenterol 
1999;94:1018-22.157. Neuschwander-Tetri BA, Clark JM, Bass NM, Van 
Natta ML, Unalp-Arida A, Tonascia J, et al; NASH 
Clinical Research Network. Clinical, laboratory and 
histological associations in adults with nonalcoholic 
fatty liver disease. Hepatology 2010;52:913-24.158. Brucknerov√° I, Benedekov√° M, Holom√°n K, Bielikov√° E, 
Kostrov√° A, Ujh√°zy E, et al. Delivery as ‚Äúphysiological 
stress‚Äù and its influence on liver enzymatic systems 
in asphyxial newborns. Biomed Pap Med Fac Univ 
Palacky Olomouc Czech Repub 2005;149:409-11.159. Rosenthal P, Haight M. Aminotransferase as a 
prognostic index in infants with liver disease. Clin 
Chem 1990;36:346-8.160.

---

### Chunk 25/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.481

e,SEQCML,Barcelona,Spain;andUnitofLiverDisease,ServicesofBiochemistryandMicrobiology,HospitalUniversitariValld‚ÄôHebron,UniversitatAut√≤nomadeBarcelona,Barcelona,SpainGregoriCasalsMercadal,CommissiononBiochemistryofLiverDisease,SEQCML,Barcelona,Spain;andServiceofBiochemistryandMolecularGenetics,HospitalCl√≠nicdeBarcelona,IDIBAPS,CIBERehd,Barcelona,Spain
MartaLalanaGarc√©s,CommissiononBiochemistryofLiverDisease,SEQCML,Barcelona,Spain;andServiceofClinicalBiochemistry,HospitalofBarbastro,Huesca,Spain
BernardoLavin,ServiceofClinicalBiochemistry,Marqu√©sdeValdecillaUniversityHospital,Santander,SpainManuelMoralesRuiz,CommissiononBiochemistryofLiverDisease,SEQCML,Barcelona,Spain;ServiceofBiochemistryandMolecularGenetics,HospitalCl√≠nicdeBarcelona,IDIBAPS,CIBERehd,Barcelona,Spain;andDepartmentofBiomedicine,SchoolofMedicineandHealthSciences,UniversidaddeBarcelona,Barcelona,
Spain
AdvLabMed2021;2(3):352‚Äì361
OpenAccess.¬©2021ArmandoRa√∫lGuerraRuizetal.,publishedbyDeGruyter.

---

### Chunk 26/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.480

; em descend√™ncia asi√°tica, ‚â•4.
- Exames laboratoriais para diferenciais:
  - Prolactina (hiperprolactinemia).
  - 17-OHP (HAC n√£o cl√°ssica).
  - TSH, T4 (¬± T3) para disfun√ß√£o tireoidiana.
  - Testosterona total/livre, DHEA-S (tumores secretores/uso ex√≥geno).
  - USG p√©lvica; RM/TC se suspeita de tumores.
  - S√≠ndrome de Cushing: cortisol salivar noturno ou teste de supress√£o com dexametasona 1 mg (se suspeita cl√≠nica).
- Achados cl√≠nicos gerais:
  - Irregularidade menstrual frequente; ciclos <21 dias, oligomenorreia >35 dias, amenorreia ‚â•3 meses ou <8 menstrua√ß√µes/ano.
  - Sangramento uterino anormal de causa ovulat√≥ria (n√£o estrutural) pode ocorrer.
  - Fen√≥tipo A (tr√™s crit√©rios presentes) com maior risco de complica√ß√µes metab√≥licas.

---

### Chunk 27/30
**Article:** A 2024 global report on national policies and hepatitis C elimination (2025)
**Journal:** The Lancet Gastroenterology & Hepatology
**Section:** abstract | **Similarity:** 0.479

33-country analysis showing only 30% met WHO HCV diagnosis targets, highlighting global gaps in elimination progress.

---

### Chunk 28/30
**Article:** Cervical Cancer Screening Recommendations: Now and for the Future (2023)
**Journal:** Healthcare (Basel)
**Section:** abstract | **Similarity:** 0.479

An√°lise comparativa das recomenda√ß√µes globais de rastreamento de c√¢ncer cervical das principais organiza√ß√µes de sa√∫de. A WHO recomenda teste de DNA-HPV a cada 5-10 anos a partir dos 30 anos, enquanto a Comiss√£o Europeia sugere teste de HPV a cada 5+ anos para 30-65 anos. Nos EUA, as diretrizes de USPSTF, ACOG, ACS e ASCO endossam teste de HPV a cada 5 anos ou alternativas baseadas em citologia. Identifica infraestrutura limitada, restri√ß√µes de recursos e lacunas na educa√ß√£o de profissionais como barreiras significativas. Enfatiza que estender intervalos de rastreamento com teste prim√°rio de HPV melhora efici√™ncia mantendo seguran√ßa. Destaca dual-stain testing para pacientes HPV-positivas e m√©todos de auto-coleta como tecnologias emergentes para melhorar acesso, particularmente em popula√ß√µes vulner√°veis.

---

### Chunk 29/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.478

olicitar e registrar par√¢metros essenciais (PCR-us, VHS); calcular √≠ndices estim√°veis (HGI, TAIG); considerar complementares (TNF-Œ±, IL-6, GPx, MDA, antioxidantes totais).
- [ ] 11. Monitorar trimestralmente HbA1c, glicemia de jejum e HGI; estabelecer metas individuais (ex.: reduzir de 6,1 para ~5,5; longo prazo ~5,3).
- [ ] 12. Calcular TG/HDL e integrar com lipidograma/SREBP1c/2; evitar combina√ß√£o de gordura saturada com a√ß√∫car e excesso de saturadas em m√∫ltiplas refei√ß√µes.
- [ ] 13. Avaliar ferro, ferritina, transferrina e satura√ß√£o (20‚Äì50%; evitar <20%); interpretar com hepcidina/SREBP1c e quadro inflamat√≥rio.
- [ ] 14. Medir TNF-Œ± (<8,1) e IL-6 (<3,4) para acompanhar atividade inflamat√≥ria; relacionar com obesidade inflamada.
- [ ] 15. Calcular HOMA-Œ≤ (167‚Äì175) e HOMA-IR (<2,15); buscar glicemia 60‚Äì90 e insulina ~6‚Äì7.
- [ ] 16. Monitorar homociste√≠na (<7,9) e PCR; usar PCR-us; documentar crises (PCR >1.000) e conduzir manejo apropriado.
- [ ] 17.

---

### Chunk 30/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.476

ors360
GuerraRuizetal.:Bilirubin:measurementandclinicalusefulness

ofacuteonchronicliverfailureandtheirpredictivevalueformortality.LiverInt2013;33:40‚Äì52.43.HelmkeS,ColmeneroJ,EversonGT.Noninvasiveassessmentofliverfunction.CurrOpinGastroenterol2015;31:199‚Äì208.44.EuropeanAssociationfortheStudyoftheLiver,ClinicalPracticeGuidelinesPanel,WendonJ,PanelMembers,CordobaJ,Dhawan
A,etal.EASLClinicalPracticalGuidelinesonthemanagementofacute(fulminant)liverfailure.JHepatol2017;66:1047‚Äì81.45.FengD,WangM,HuJ,LiS,ZhaoS,LiH,etal.Prognosticvalueofthealbumin‚Äìbilirubingradeinpatientswithhepatocellularcarcinomaandotherliverdiseases.AnnTranslMed2020;8:553.46.L√≥pez-Vel√°zquezJA,Ch√°vez-TapiaNC,Ponciano-Rodr√≠guezG,S√°nchez-ValleV,CaldwellSH,UribeM,etal.Bilirubinaloneasa
biomarkerforshort-termmortalityinacute-on-chronicliverfailure:animportantprognosticindicator.AnnHepatol2014;13:98‚Äì104.47.BreimerLH,WannametheeG,EbrahimS,ShaperAG.Serumbilirubinandriskofischemicheartdiseaseinmiddle-agedBritishmen.Cl

---

